What are the risks to patients of stem cell transplants?

Stem cell transplantation is a complex process. However, the transplant procedure itself is straightforward, similar in fact to a blood transfusion.

The donor stem cells are transfused through a central line (a catheter) which goes into a major vein in the chest.

The donor stem cells travel through the circulatory system and the stem cells can then start homing to the bone marrow and start dividing and replenishing the immune and blood system.

Chemotherapy and Infection

Once a stem cell transplant has taken place it can take several weeks or months for the donor cells to engraft. Engraftment means the stem cells have started to proliferate (reproduce themselves) within the recipient host.

Before stem cells can be transplanted a patient must undergo high dose chemotherapy. Following transfusion, the patient must be isolated for several weeks or months to avoid infection and to give the donated stem cells a chance to grow and proliferate.

While a patient is waiting for a stem cell transplant to engraft their immune system is severely compromised, because chemotherapy has essentially destroyed it. Therefore, infections before the donated stem cells successfully engraft can be serious and sometimes fatal – this is why patients are kept in isolation for several months, while their body and the donor stem cells grow a corrected, fully functional immune system.

Chemotherapy has significant side effects on the digestive system and sometimes on the body as a whole. Adults cannot withstand the levels of toxicity in chemotherapy that children invariably can and in elderly patients the risk is greater still.

Transplant Failure and GvHD

Failure to engraft, otherwise known as transplant rejection, is another risk. This means the donor recipient’s body has decided the donor stem cells are a threat, rejecting them.

In some cases, transplanted cells and the recipient’s cells can clash in the opposite way, causing what is called “graft versus host disease” (GvHD). This is where the donor cells attack the person who has received the transplant.

GvHD can happen within days of transplants – and up to two years later.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    WideCells Group PLC

    More articles like this

    WideCells Group PLC

    The dangers of unregulated stem cell “therapies”

    Professor Peter Hollands, WideCell’s Group Chief Scientific Officer, comments on unethical and unproven stem cell “therapies” and advises on how to sort the snake oil promises from the genuine science: The early 21st century offers some

    WideCells Group PLC

    WHY STORE STEM CELLS?

    Protect your family and ensure your medical wealth for generations to come. Umbilical cord blood stem cell transplantation has increased by 300% over the last 13 years globally thanks to their use to treat over 80 different blood

    WideCells Group PLC

    Essential Thrombocythaemia and treatment using stem cell therapies

    What is Essential Thrombocythaemia? Essential Thrombocythaemia is a rare blood disorder caused by an overproduction of megakaryocytes, the cells responsible for making platelets in our bone marrow. Essential Thrombocythaemia is a myeloproliferative neoplasm, part of a

    WideCells Group PLC

    Why should I store my child’s stem cells?

    Stem cells have a great potential importance in the future of healthcare. They are capable of repairing and replacing different cell types in the body. With advancements in technology, it is hoped stem cells will be

    WideCells Group PLC

    Are we on the brink of a stem cell revolution?

    It has now been decades since stem cell technology emerged as the next great breakthrough in modern medicine, with the bold potential for one day curing everything from heart disease to cancer. Today, that optimism doesn’t appear to

    WideCells Group PLC

    Revista Business Magazine Portugal: Widecells Group PLC

    Investments that ensure the future WideCells Group’s mission is to make stem cell therapies globally accessible. The group consists of 3 divisions. CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical

    WideCells Group PLC

    The principles of Regenerative Medicine

    Professor Peter Hollands, WideCells Group Chief Scientific Officer, gives an overview of the principles of Regenerative Medicine: Regenerative Medicine is nothing new. It has been practised since the first bone marrow transplant in the 1950s to